# Gateway Neuroscience
## October 29, 2024



### PubChem Search: zelquistinel (NMDAR)

| drug_name    | active_ingredient   |       cid | sid                    | compound_synonyms                                                                                                                                                                                                                                                                                                                                                                                           | substance_synonyms                                                                                                                                                                                                                       | description   | pubmed_ids   | link                                                |
|:-------------|:--------------------|----------:|:-----------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:--------------|:-------------|:----------------------------------------------------|
| zelquistinel | NMDAR               | 132155398 | [472419464, 387065541] | ['NMDAR', 'CS-0116348', 'DA-59265', 'tert-butyl (4S)-2-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-3-oxo-2,5-diazaspiro[3.4]octane-5-carboxylate', 'UNII-387WYR6N95', 'GATE-251', 'GATE251', 'HY-109164', 'Zelquistinel [INN]', '387WYR6N95', '2151842-64-5', 'AGN241751', 'G18567', 'Zelquistinel', 'CHEMBL5314944', 'zelquistinel', 'MS-24891', 'Zelquistinel [WHO-DD]', 'AGN-241751', 'SCHEMBL19628505'] | ['zelquistinel', 'NMDAR', '387WYR6N95', '2151842-64-5', 'N-methyl-D-aspartate receptor', 'GATE251', 'GATE-251', 'AGN241751', 'Zelquistinel [WHO-DD]', 'Zelquistinel [INN]', 'Zelquistinel', '4R3XO922WS', 'AGN-241751', 'NMDA RECEPTOR'] |               |              | https://pubchem.ncbi.nlm.nih.gov/compound/132155398 |
### NMDA
**FDA Approvals**

> * No Approved Drugs Found


**Clinical Trial Sponsors**
![sponsor_plot](images/sponsor_plot_NMDA.png)

| Search Term   | NCT Number   | Study Title                                                                                       | Study URL                                    | Acronym    | Study Status   | Brief Summary                                                                                                                                                                                                                                                                                 | Study Results   | Conditions                           | Interventions                    | Sponsor            | Collaborators   | Phases   |   Enrollment | Funder Type   | Study Type     | Start Date   | Primary Completion Date   | Completion Date   | First Posted   | Results First Posted   | Last Update Posted   | Locations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Study Documents                                                                                                                                                                       |
|:--------------|:-------------|:--------------------------------------------------------------------------------------------------|:---------------------------------------------|:-----------|:---------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----------------|:-------------------------------------|:---------------------------------|:-------------------|:----------------|:---------|-------------:|:--------------|:---------------|:-------------|:--------------------------|:------------------|:---------------|:-----------------------|:---------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ['uplizna']   | NCT04372615  | The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis                                        | https://clinicaltrials.gov/study/NCT04372615 | ExTINGUISH | RECRUITING     | Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo. | NO              | Autoimmune Encephalitis|Encephalitis | DRUG: Inebilizumab|DRUG: Placebo | University of Utah |                 | PHASE2   |          116 | OTHER         | INTERVENTIONAL | 2022-03-30   | 2025-10-31                | 2026-08-31        | 2020-05-04     |                        | 2023-07-21           | University of Alabama at Birmingham, Birmingham, Alabama, 35233, United States|St. Joseph Hospital and Medical Center Barrow Neurological Institute, Phoenix, Arizona, 85013, United States|UC Irvine, Orange, California, 92868, United States|UC Davis, Sacramento, California, 95816, United States|Yale University, New Haven, Connecticut, 06510, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, 32224, United States|University of Miami, Miami, Florida, 33136, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, 60611, United States|University of Iowa, Iowa City, Iowa, 52242, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States|University of Michigan Health System, Ann Arbor, Michigan, 48109, United States|Washington University in St. Louis School of Medicine, Saint Louis, Missouri, 63110, United States|SUNY Downstate, Brooklyn, New York, 11203, United States|Mount Sinai, New York, New York, 10029, United States|Columbia University Medical Center, New York, New York, 10033, United States|University of Rochester, Rochester, New York, 14618, United States|SUNY Buffalo, Williamsville, New York, 14221, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27101, United States|University of Cincinnati, Cincinnati, Ohio, 45219, United States|Ohio State University, Columbus, Ohio, 43210, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, 15213, United States|Vanderbilt University, Nashville, Tennessee, 37212, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|University of Utah, Salt Lake City, Utah, 84108, United States|University of Virginia, Charlottesville, Virginia, 22903, United States|Erasmus Medical University Center, Rotterdam, Netherlands|Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain |                                                                                                                                                                                       |
| ['cbd']       | NCT03362879  | COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel | https://clinicaltrials.gov/study/NCT03362879 | COSMOS     | COMPLETED      | The purpose of this study is to evaluate treatment of advanced Parkinson's Disease (PD) patients on levodopa-carbidopa intestinal gel (LCIG) monotherapy in a routine clinical setting.                                                                                                       | YES             | Parkinson's Disease (PD)             |                                  | AbbVie             |                 |          |          412 | INDUSTRY      | OBSERVATIONAL  | 2017-12-14   | 2018-12-17                | 2018-12-17        | 2017-12-05     | 2020-01-06             | 2020-01-06           | Gailtal Klinik /ID# 202505, Hermagor-Pressegger See, Kaernten, 9620, Austria|Medizinische Universität Graz /ID# 202559, Graz, Steiermark, 8010, Austria|University of Calgary /ID# 206550, Calgary, Alberta, T2N 4Z6, Canada|Ottawa Hospital /ID# 169448, Ottawa, Ontario, K1Y 4E9, Canada|Toronto Western Hospital /ID# 169038, Toronto, Ontario, M5T 2S8, Canada|Clinique Neuro Levis /ID# 206549, Lévis, Quebec, G6W 0M5, Canada|Clinical Hosp Center Zagreb /ID# 203553, Zagreb, 10000, Croatia|Fakultni nemocnice u sv. Anny v Brne /ID# 209774, Brno 2, Brno-mesto, 602 00, Czechia|Fakultni Nemocnice Olomouc /ID# 209776, Olomouc, Olomoucky Kraj, 779 00, Czechia|Vseobecna Fakultni Nemocnice /ID# 209775, Prague, 128 08, Czechia|Aiginiteio University Hospital /ID# 203476, Athens, Attiki, 11528, Greece|HYGEIA Hospital /ID# 203474, Athens, 15123, Greece|Mediterraneo Hospital /ID# 203472, Glyfada, 16675, Greece|University Hospital of Ioannin /ID# 203471, Ioannina, 45500, Greece|Pecsi Tudomanyegyetem /ID# 170026, Pécs, Pecs, 7624, Hungary|Semmelweis Egyetem /ID# 170025, Budapest, 1083, Hungary|Borsod-Abauj-Zemplen Megyei /ID# 170027, Miskolc, 3526, Hungary|Szegedi Tudomanyegyetem /ID# 170028, Szeged, 6720, Hungary|Bon Secours Hospital /ID# 168424, Cork, T12 DV56, Ireland|University Hospital Galway /ID# 170754, Galway, H91 YR71, Ireland|Tel Aviv Sourasky Medical Ctr /ID# 167542, Tel Aviv-Yafo, Tel-Aviv, 6423906, Israel|Sheba Medical Center /ID# 167543, Ramat Gan, 5262100, Israel|Clinic Fundeni Institute /ID# 169265, Bucharest, Bucuresti, 022328, Romania|Colentina Clinical Hospital /ID# 169263, Bucharest, 20125, Romania|Emergency Clinical County Hosp /ID# 169269, Targu Mures, 540042, Romania|Timisoara County /ID# 169266, Timisoara, 300736, Romania|Timisoara County /ID# 169268, Timisoara, 300736, Romania|AbbVie Farmaceutica SLU /ID# 164364, Madrid, Spain|Centrum for neurologi /ID# 171391, Stockholm, 113 65, Sweden|Neurologmottagningen /ID# 171390, Stockholm, 171 76, Sweden                                                 | Study Protocol, https://cdn.clinicaltrials.gov/large-docs/79/NCT03362879/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/79/NCT03362879/SAP_001.pdf |

### depression
**FDA Approvals**

|   fda_year |   fda_year_approval_count | fda_drug_name   | fda_active_ingredient   | fda_approval_date   | fda_approved_use                                                                     | fda_drug_link                                                                                    | fda_press_release                                                                                           | fda_drug_trials_snapshot                                                              | fda_2_drug_name   | fda_2_active_ingredient   | fda_2_dosage_form           | fda_2_drug_link                                                                                | fda_2_application_type   |   fda_2_application_num | fda_2_sponsor   | sponsor   |
|-----------:|--------------------------:|:----------------|:------------------------|:--------------------|:-------------------------------------------------------------------------------------|:-------------------------------------------------------------------------------------------------|:------------------------------------------------------------------------------------------------------------|:--------------------------------------------------------------------------------------|:------------------|:--------------------------|:----------------------------|:-----------------------------------------------------------------------------------------------|:-------------------------|------------------------:|:----------------|:----------|
|       2023 |                        30 | Zurzuvae        | zuranolone              | 2023-08-04 00:00:00 | To treat postpartum depression¬†Press ReleaseDrug Trials Snapshot                    | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217369s000lbl.pdf                      | https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depression | https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zurzuvae | ZURZUVAE          | ZURZUVAE (ZURANOLONE)     | ['CAPSULE', 'ORAL']         | https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217369 | NDA                      |                  217369 | BIOGEN INC      | Biogen    |
|       2019 |                         4 | Zulresso        | brexanolone             | 2019-03-19 00:00:00 | To treat postpartum depression (PPD) in adult womenPress ReleaseDrug Trials Snapshot | http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211371 | https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-post-partum-depression     | https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zulresso | ZULRESSO          | ZULRESSO (BREXANOLONE)    | ['SOLUTION', 'INTRAVENOUS'] | https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211371 | NDA                      |                  211371 | SAGE THERAP     | Sage      |

**Clinical Trial Sponsors**
![sponsor_plot](images/sponsor_plot_depression.png)

| Search Term                                   | NCT Number   | Study Title                                                                                                           | Study URL                                    | Acronym    | Study Status          | Brief Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Study Results   | Conditions                                                                                                                                  | Interventions                                                                                                                                                                                         | Sponsor                                | Collaborators                                                                                        | Phases   |   Enrollment | Funder Type   | Study Type     | Start Date   | Primary Completion Date   | Completion Date   | First Posted   | Results First Posted   | Last Update Posted   | Locations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Study Documents                                                                                                                                                                                                                                                                   |
|:----------------------------------------------|:-------------|:----------------------------------------------------------------------------------------------------------------------|:---------------------------------------------|:-----------|:----------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----------------|:--------------------------------------------------------------------------------------------------------------------------------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:---------------------------------------|:-----------------------------------------------------------------------------------------------------|:---------|-------------:|:--------------|:---------------|:-------------|:--------------------------|:------------------|:---------------|:-----------------------|:---------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ['cbd']                                       | NCT05103618  | Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA | https://clinicaltrials.gov/study/NCT05103618 | FDOPAOM    | NOT_YET_RECRUITING    | The purpose of this research is to use 18 F Fluorodopa positron emission tomography (FDOPA PET) to measure dopamine function, and utilize magnetic resonance imaging (MRI) to measure inflammatory and oxidative stress markers in persons with Parkinson's disease.The overall goal of this study will be to further the understanding of the effects of a novel meditation technique called orgasmic meditation (OM) on these neurophysiological parameters.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | NO              | Parkinson Disease|Idiopathic Parkinson Disease                                                                                              | DRUG: [F-18] Fluorodopa Positron Emission Tomography|BEHAVIORAL: OM Meditation                                                                                                                        | Andrew Newberg                         |                                                                                                      | PHASE2   |           80 | OTHER         | INTERVENTIONAL | 2024-09      | 2026-06-01                | 2026-06-01        | 2021-11-02     |                        | 2024-03-26           | Thomas Jefferson University, Marcus Institute of Integrative Health Centers, Philadelphia, Pennsylvania, 19107, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Informed Consent Form, https://cdn.clinicaltrials.gov/large-docs/18/NCT05103618/ICF_001.pdf                                                                                                                                                                                       |
| ['e+2007']                                    | NCT06028503  | ACT Intervention for Type 2 Diabetes Management for Rural and Underserved Community                                   | https://clinicaltrials.gov/study/NCT06028503 |            | RECRUITING            | The purpose of this project is to examine the feasibility/acceptability of a one-day Acceptance and Commitment Therapy + Lifestyle Education group intervention paired with 12-weeks of Continuous Glucose Monitoring for patients with type 2 diabetes (T2D) living in rural communities. This study is being designed as a randomized control trial (RCT) comparing ACT+LE+CGM to LE+CGM to LE. The ultimate goal of this line of research is that a community-wide intervention of Acceptance and Commitment Therapy (ACT) with Continuous Glucose Monitoring (CGM) and Lifestyle Education (LE) will improve T2D outcomes in rural communities compared to CGM and LE, or LE alone. Our goal is to develop a scalable and sustainable program for diabetes management in rural areas that enables individual self-management and does not require extensive healthcare resources in an existing medical desert.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | NO              | Type 2 Diabetes                                                                                                                             | BEHAVIORAL: Acceptance and Commitment Therapy|DEVICE: Abbott FreeStyle® Libre® 3|OTHER: Generic Education                                                                                             | Sam Houston State University           | Chelsea Ratcliff, Ph.D.|Owen Kelly, Ph.D.,RNutr|Oluwaseun Olaiya, DO|Michael Griffin, Ph.D.          | NA       |           60 | OTHER         | INTERVENTIONAL | 2024-04-01   | 2025-08-31                | 2026-08-31        | 2023-09-08     |                        | 2024-04-19           | Sam Houston State University College of Osteopathic Medicine, Conroe, Texas, 77304, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Study Protocol, Statistical Analysis Plan, and Informed Consent Form, https://cdn.clinicaltrials.gov/large-docs/03/NCT06028503/Prot_SAP_ICF_000.pdf                                                                                                                               |
| ['a26']                                       | NCT06299319  | Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD            | https://clinicaltrials.gov/study/NCT06299319 | PAP-OCD    | NOT_YET_RECRUITING    | Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. There is interest to see if similar effects may be provided in those with obsessive compulsive disorder (OCD).The purpose of this study is to evaluate the safety, feasibility, and clinical effects of psilocybin administration in those with OCD. Ten participants with treatment-resistant OCD will receive two doses of 25mg of psilocybin under supportive conditions, two weeks apart. The investigators hypothesize that two sessions of psilocybin 25mg administered under supportive conditions to participants with treatment-resistant OCD will lead to significant reductions in OCD symptoms.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | NO              | Obsessive-Compulsive Disorder                                                                                                               | DRUG: Psilocybin                                                                                                                                                                                      | Centre for Addiction and Mental Health |                                                                                                      | PHASE1   |           10 | OTHER         | INTERVENTIONAL | 2024-04      | 2024-06                   | 2024-09           | 2024-03-07     |                        | 2024-03-07           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/19/NCT06299319/Prot_SAP_000.pdf                                                                                                                                                           |
| ['efd']                                       | NCT06109493  | Effects of an ACT-based Psychological Treatment in Patients With Chronic Kidney Disease                               | https://clinicaltrials.gov/study/NCT06109493 |            | RECRUITING            | Investigation of the efficacy of Acceptance and Commitment Therapy (ACT) for the psychological treatment of patients with chronic kidney disease.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | NO              | Chronic Kidney Diseases|Depression                                                                                                          | BEHAVIORAL: ACT                                                                                                                                                                                       | Universidad Europea de Madrid          | Fundación Renal Iñigo Alvarez De Toledo|Centro de Enseñanza Superior Cardenal Cisneros               | NA       |          104 | OTHER         | INTERVENTIONAL | 2023-11-01   | 2024-10-31                | 2025-07-31        | 2023-10-31     |                        | 2024-04-09           | Fundación Renal Iñigo Alvarez de Toledo, Madrid, 28003, Spain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/93/NCT06109493/Prot_SAP_000.pdf|Informed Consent Form, https://cdn.clinicaltrials.gov/large-docs/93/NCT06109493/ICF_001.pdf                                                               |
| ['example+9']                                 | NCT05986370  | The METRIC Study Protocol                                                                                             | https://clinicaltrials.gov/study/NCT05986370 | METRIC     | RECRUITING            | The goal of this clinical trial is to test the effects of spinal manipulative therapy in individuals with chronic primary low back pain and determine the neurophysiological mechanisms underlying pain relief. The main questions it aims to answer are: • Is pain relief produced by spinal manipulative therapy in patients with chronic primary low back pain caused by a reduction of C-fiber-related nociceptive processing? • Are these effects greater when spinal manipulative therapy is applied to the whole spine where it is clinically indicated compared with lumbar spine only? • Are these effects greater after 36 treatments over 3 months compared with 12 treatments over 1 month. Participants will receive spinal manipulative therapy (all clinically indicated spine segments or back only) or a control intervention. A group of healthy volunteers will be recruited to assess secondary outcome measures over the same time period, as reference data for comparisons. Researchers will compare the two groups receiving spinal manipulative therapy to the group receiving the control intervention to see if clinical pain relief and the reduction of temporal summation of second pain (produced experimentally) is significantly greater with spinal manipulative therapy.                                                                                                                                                                                                                                                                                                                                         | NO              | Chronic Low-back Pain                                                                                                                       | PROCEDURE: lumbar spinal manipulative therapy|PROCEDURE: sham spinal manipulative therapy|PROCEDURE: full spine spinal manipulative therapy                                                           | Université du Québec à Trois-Rivières  |                                                                                                      | NA       |          112 | OTHER         | INTERVENTIONAL | 2023-10-25   | 2025-09-29                | 2026-12-31        | 2023-08-14     |                        | 2023-12-04           | Université du Québec à Trois-Rivières, Trois-Rivières, Quebec, G8Z 4M3, Canada                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/70/NCT05986370/SAP_000.pdf                                                                                                                                                                                   |
| ['a-a-1']                                     | NCT06081972  | Towards a Food Ingredient Clinically Proven to Benefit Gut Health: Novel RG-I Variants                                | https://clinicaltrials.gov/study/NCT06081972 | NUTRIGUT   | RECRUITING            | The aim of this study is to determine, quantify and understand the potential prebiotic effects of RG-I variants via microbiota modulation. The anti-inflammatory potential effects of these variants will also be investigated.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | NO              | Healthy                                                                                                                                     | DIETARY_SUPPLEMENT: Maltodextrin|DIETARY_SUPPLEMENT: Chicory RG-I|DIETARY_SUPPLEMENT: Carrot RG-I                                                                                                     | Örebro University, Sweden              | NutriLeads B.V. (Wageningen, The Netherlands)|ProDigest (Ghent, Belgium)|Ambiotis (Toulouse, France) | NA       |           75 | OTHER         | INTERVENTIONAL | 2023-10-02   | 2024-04-30                | 2024-12-31        | 2023-10-13     |                        | 2023-11-01           | Campus USÖ, Örebro, 703 62, Sweden|Campus USÖ, Örebro, 703 62, Sweden                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/72/NCT06081972/Prot_SAP_000.pdf                                                                                                                                                           |
| ['example+9']                                 | NCT05734638  | Stress and Blood Pressure Management for Caregivers                                                                   | https://clinicaltrials.gov/study/NCT05734638 | Stress/HTN | RECRUITING            | Due to health and wealth disparities, no demographic group is more at risk than African American women for the double jeopardy of stress from caregiving for persons living with dementia (PLWD) and stress associated with hypertension (HTN). This double jeopardy puts those they care for in jeopardy as well: Reduced quality of life and longevity, disability, cognitive decline, and stroke associated with HTN1 impede caregiving activities and resultant health and well-being for persons living with Alzheimer's disease and related dementias (ADRD). Although successful multi-component interventions have addressed ADRD caregiver stress (REACH II) and the Savvy Caregiver program, to our knowledge there are no interventions that target the complexity of chronic caregiving stress and HTN self-care for African American women caregivers of persons living with ADRD.This project will test two interventions for their effectiveness in improving outcomes for the target group: Mindfulness in Motion (MIM) and the Dietary Approaches to Stop Hypertension (DASH). MIM includes mindful awareness and movement from a seated position, breathing exercises, healthy sleep, and guided mindfulness meditation. The DASH component will be tailored for Black Americans. It uses a critical thinking approach that involves problem solving, participant-centered goal setting, health coaching, reflection, and development of self-efficacy (confidence) to promote physical activity and healthy eating. Solid empirical evidence demonstrates its effectiveness in reducing blood pressure among mixed-race samples. | NO              | Hypertension|Stress, Psychological                                                                                                          | BEHAVIORAL: MIM-DASH|BEHAVIORAL: MIM Only|BEHAVIORAL: DASH Only                                                                                                                                       | Ohio State University                  | Robert Wood Johnson Foundation                                                                       | NA       |           90 | OTHER         | INTERVENTIONAL | 2023-09-11   | 2025-09-30                | 2026-09-30        | 2023-02-21     |                        | 2023-09-28           | Ohio State University, Columbus, Ohio, 43210, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/38/NCT05734638/Prot_SAP_000.pdf|Informed Consent Form, https://cdn.clinicaltrials.gov/large-docs/38/NCT05734638/ICF_001.pdf                                                               |
| ['icq']                                       | NCT04696861  | Telehealth to Reduce Suicidality and Improve HIV Care Engagement in Tanzania                                          | https://clinicaltrials.gov/study/NCT04696861 |            | ACTIVE_NOT_RECRUITING | The overall objectives of the proposed research are to develop a brief telehealth counseling intervention to provide support for people living with HIV and experiencing suicidal ideation, and to support HIV care engagement. The investigators hypothesize that a brief telehealth counseling intervention will be safe (participants in the clinical trial will not have increased risk of suicidal behavior), acceptable (high patient retention and satisfaction, high fidelity), and will demonstrate preliminary efficacy (reduced suicidal ideation, improved care engagement, improved mental well-being).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | NO              | Suicide|Suicidal Ideation|HIV Infections|Adherence, Medication|Treatment Adherence and Compliance|Stigma, Social|Disclosure|Quality of Life | BEHAVIORAL: IDEAS for Hope|BEHAVIORAL: Enhanced Standard of Care (Safety Planning)                                                                                                                    | Duke University                        | National Institute of Mental Health (NIMH)|Kilimanjaro Christian Medical Centre, Tanzania            | NA       |           60 | OTHER         | INTERVENTIONAL | 2023-05-17   | 2023-12-08                | 2025-03-31        | 2021-01-06     |                        | 2024-02-05           | Majengo Health Centre, Moshi, Tanzania|Mawenzi Hospital, Moshi, Tanzania                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Informed Consent Form, https://cdn.clinicaltrials.gov/large-docs/61/NCT04696861/ICF_000.pdf                                                                                                                                                                                       |
| ['oral+semaglutide', 'semaglutide', 'wegovy'] | NCT05702905  | Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome    | https://clinicaltrials.gov/study/NCT05702905 |            | RECRUITING            | To investigate the efficacy of semaglutide in obese infertile women of childbearing age with polycystic ovary syndrome (PCOS), we design this prospective, randomized, open and controlled study. 75 obese infertile PCOS patients will be recruited and randomized into three groups: metformin, semaglutide and metformin+semaglutide, on the basis of calorie-restricted diet and physical exercise. All subjects will be treated for 12 weeks, and then stop taking the drug for at least 8 weeks to initiate ovulation induction or ovulation induction combined with artificial insemination. All subjects will be followed up for 24 weeks for pregnancy outcome. The primary endpoint of the study is the percentage of weight loss at 12 weeks of treatment. The secondary endpoints include HOMA-IR and androgen levels at 12 weeks of treatment, ovulation rate at 24 weeks of follow-up, clinical pregnancy rate and cumulative pregnancy rate, and depression, anxiety, diet and quality of life scores at 12 weeks of treatment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | NO              | PCOS (Polycystic Ovary Syndrome)|Semaglutide                                                                                                | DRUG: Metformin Hydrochloride 500 MG|DRUG: Semaglutide, 1.34 mg/mL|DRUG: Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG|BEHAVIORAL: calorie-restricted diet|BEHAVIORAL: physical exercise | Peking University First Hospital       |                                                                                                      | PHASE4   |           75 | OTHER         | INTERVENTIONAL | 2023-05-09   | 2024-12-31                | 2025-06-30        | 2023-01-27     |                        | 2024-03-25           | PekingUFH, Peking, Beijing, 100034, China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Study Protocol, https://cdn.clinicaltrials.gov/large-docs/05/NCT05702905/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/05/NCT05702905/SAP_001.pdf                                                                                             |
| ['example+9']                                 | NCT05833503  | Integrative Couple Treatment for Gambling/Substance Use Disorder                                                      | https://clinicaltrials.gov/study/NCT05833503 |            | RECRUITING            | The aim of the study is to compare couple-based treatment to individual treatment (treatment as usual) for addiction (gambling or substance use disorder).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | NO              | Gambling Disorder|Substance Use Disorders                                                                                                   | BEHAVIORAL: Integrative Couple Treatment for Addiction (ICT-A)|BEHAVIORAL: Treatment individual as usually offered                                                                                    | Université du Québec à Trois-Rivières  | Université du Québec a Montréal|Université de Sherbrooke|Laval University|Université de Montréal     | NA       |          100 | OTHER         | INTERVENTIONAL | 2023-05-01   | 2025-08                   | 2026-02           | 2023-04-27     |                        | 2024-04-11           | Centre Intégré de Santé et de Services Sociaux de Lanaudière, Joliette, Quebec, J6E 5X7, Canada|Centre intégré de Santé et de Services Sociaux de Chaudière-Appalaches (CISSS-CA), Lévis, Quebec, G6V 0M4, Canada|Centre Universitaire Intégré de Santé et de Services Sociaux du Centre Sud de l'Ile de Montréal, Montréal, Quebec, H2L 4M1, Canada|Centre Intégré de Santé et de Services Sociaux des Laurentides, Saint-Jérôme, Quebec, J7Z 5T3, Canada|Centre Universitaire Intégré de Santé et de Services Sociaux de l'Estrie, Sherbrooke, Quebec, J1G 1B1, Canada|Centre Intégré de Santé et de Services Sociaux de la Montérégie-Ouest, St-Hubert, Quebec, J3Y 6W9, Canada|Centre Universitaire Intégré de Santé et de Services Sociaux de la Capitale Nationale, Québec, G1J 0A4, Canada | Study Protocol, https://cdn.clinicaltrials.gov/large-docs/03/NCT05833503/Prot_005.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/03/NCT05833503/SAP_006.pdf|Informed Consent Form, https://cdn.clinicaltrials.gov/large-docs/03/NCT05833503/ICF_007.pdf |

### cognitive impairment
**FDA Approvals**

|   fda_year |   fda_year_approval_count | fda_drug_name   | fda_active_ingredient   | fda_approval_date   | fda_approved_use                                                                                                                                                                                                                                                                            | fda_drug_link                                                                                                                                                                               |   fda_press_release |   fda_drug_trials_snapshot | fda_2_drug_name   | fda_2_active_ingredient   | fda_2_dosage_form           | fda_2_drug_link                                                                                | fda_2_application_type   |   fda_2_application_num | fda_2_sponsor        | sponsor          |
|-----------:|--------------------------:|:----------------|:------------------------|:--------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------:|---------------------------:|:------------------|:--------------------------|:----------------------------|:-----------------------------------------------------------------------------------------------|:-------------------------|------------------------:|:---------------------|:-----------------|
|       2012 |                         9 | Amyvid          | Florbetapir F 18        | 2012-04-06 00:00:00 | Used as a radioactive diagnostic agent for Positron Emission Tomography (PET) imaging of the brain to estimate Œ≤-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer‚Äôs Disease (AD) and other causes of cognitive decline. | https://wayback.archive-it.org//7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202008&SearchType=BasicSearch |                 nan |                        nan | AMYVID            | AMYVID (FLORBETAPIR F-18) | ['SOLUTION', 'INTRAVENOUS'] | https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202008 | NDA                      |                  202008 | AVID RADIOPHARMS INC | Avid Radiopharms |

**Clinical Trial Sponsors**
![sponsor_plot](images/sponsor_plot_cognitive impairment.png)

| Search Term                                                                                                                                                                             | NCT Number   | Study Title                                                                                                                              | Study URL                                    | Acronym    | Study Status          | Brief Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Study Results   | Conditions                                                                                                           | Interventions                                                                                                                                                                                                                                                                       | Sponsor                                                                   | Collaborators                                                                                                                                                                  | Phases        |   Enrollment | Funder Type   | Study Type     | Start Date   | Primary Completion Date   | Completion Date   | First Posted   | Results First Posted   | Last Update Posted   | Locations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Study Documents                                                                                                                                                                                                                                                                                                                                                                                                               |
|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:-------------|:-----------------------------------------------------------------------------------------------------------------------------------------|:---------------------------------------------|:-----------|:----------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----------------|:---------------------------------------------------------------------------------------------------------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:--------------------------------------------------------------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:--------------|-------------:|:--------------|:---------------|:-------------|:--------------------------|:------------------|:---------------|:-----------------------|:---------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ['example+9']                                                                                                                                                                           | NCT06080932  | Ketogenic Intervention in Depression                                                                                                     | https://clinicaltrials.gov/study/NCT06080932 | KIND       | RECRUITING            | The goal of this study is to examine whether a well-formulated ketogenic diet (KD) can be implemented into a university counseling treatment program for major depression and to test whether such a program has any benefit on mental and metabolic health.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | NO              | Depression|Ketosis                                                                                                   | OTHER: Ketogenic Diet|OTHER: NIH Toolbox|OTHER: gradCPT|OTHER: Resting-state fMRI|OTHER: Task-fMRI|OTHER: CGM/CKM|BIOLOGICAL: Blood Draw|OTHER: Sleep Monitoring|BIOLOGICAL: Ketone/Glucose Monitoring|OTHER: Body Composition|BEHAVIORAL: PHQ-9|BEHAVIORAL: WHO-5|BEHAVIORAL: SKID | Ohio State University                                                     |                                                                                                                                                                                | NA            |           30 | OTHER         | INTERVENTIONAL | 2023-02-20   | 2024-06                   | 2024-12           | 2023-10-12     |                        | 2024-04-02           | The Ohio State University, Columbus, Ohio, 43210, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Study Protocol, https://cdn.clinicaltrials.gov/large-docs/32/NCT06080932/Prot_000.pdf|Informed Consent Form, https://cdn.clinicaltrials.gov/large-docs/32/NCT06080932/ICF_001.pdf                                                                                                                                                                                                                                             |
| ['chd']                                                                                                                                                                                 | NCT05735041  | Computerized Cognitive Training in Patients With Coronary Heart Disease and Mild Cognitive Impairment                                    | https://clinicaltrials.gov/study/NCT05735041 | COG-T CHD  | ACTIVE_NOT_RECRUITING | In this study, a multicentre, double-blind, randomized controlled study based on cognitive training was conducted in patients with coronary heart disease and cognitive impairment but without dementia， to evaluate the effectiveness of computer-based digital therapy in improving the cognitive function of such patients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | NO              | Mild Cognitive Impairment|Coronary Heart Disease                                                                     | BEHAVIORAL: Multi-domain cognitive digital therapy|BEHAVIORAL: Basic cognitive therapy                                                                                                                                                                                              | Beijing Anzhen Hospital                                                   | Beijing Wispirit Technology Co., Ltd                                                                                                                                           | NA            |          224 | OTHER         | INTERVENTIONAL | 2023-01-18   | 2024-12-31                | 2025-07-31        | 2023-02-21     |                        | 2024-02-21           | Beijing Anzhen Hospital, Beijing, China|Beijing Sixth Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|The second hospital of Chifeng, Chifeng, China|Handan Central Hospital, Handan, China|Inner Mongolia Ordos Central Hospital Kangbashi Department, Ordos, China|The First Affiliated Hospital of Hebei North University, Shijiazhuang, China|The First Hospital of Hebei Medical University, Zhangjiakou, China                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/41/NCT05735041/SAP_000.pdf                                                                                                                                                                                                                                                                                                                               |
| ['vortioxetine']                                                                                                                                                                        | NCT04895488  | Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia                                                                        | https://clinicaltrials.gov/study/NCT04895488 | CAVES      | RECRUITING            | Clinical trial to assess the efficacy of Vortioxetine compared with treatment as usual in early schizophrenia.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | NO              | Cognitive Impairment With Primary Psychotic Disorder|Negative Symptoms With Primary Psychotic Disorder               | DRUG: Vortioxetine|DRUG: Usual Antipsychotic Treatment                                                                                                                                                                                                                              | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |                                                                                                                                                                                | PHASE2|PHASE3 |           37 | OTHER         | INTERVENTIONAL | 2022-01-20   | 2024-12-20                | 2025-12-20        | 2021-05-20     |                        | 2024-02-26           | Hospital Universitario Virgen del Rocío, Sevilla, 41013, Spain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Study Protocol, https://cdn.clinicaltrials.gov/large-docs/88/NCT04895488/Prot_000.pdf                                                                                                                                                                                                                                                                                                                                         |
| ['suv', 'florbetapir+f18', 'amyvid', '18f-av45', 'florbetapir-fluorine-18', 'florbetapir,+f-18', 'aducanumab-avwa', 'florbetapir+f+18', 'florbetapir+f-18', '18f-av-45', 'florbetapir'] | NCT05108922  | A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) | https://clinicaltrials.gov/study/NCT05108922 |            | COMPLETED             | The main purpose of this study is to compare donanemab to aducanumab on brain amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | YES             | Mild Cognitive Impairment (MCI)|Alzheimer Disease                                                                    | DRUG: Donanemab|DRUG: Aducanumab                                                                                                                                                                                                                                                    | Eli Lilly and Company                                                     |                                                                                                                                                                                | PHASE3        |          148 | INDUSTRY      | INTERVENTIONAL | 2021-11-16   | 2022-09-09                | 2023-09-19        | 2021-11-05     | 2023-11-02             | 2023-11-02           | Neurology Center of North Orange County, Fullerton, California, 92835, United States|Irvine Clinical Research, Irvine, California, 92614, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, 91403, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, 06510, United States|JEM Research Institute, Atlantis, Florida, 33462, United States|Brain Matters Research, Delray Beach, Florida, 33445, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, 33912, United States|Infinity Clinical Research, LLC, Hollywood, Florida, 33024, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, 32216, United States|Charter Research - Lady Lake, Lady Lake, Florida, 32159, United States|ClinCloud - Maitland, Maitland, Florida, 32751, United States|ClinCloud - Viera, Melbourne, Florida, 32940, United States|Merritt Island Medical Research, LLC, Merritt Island, Florida, 32952, United States|Optimus U Corporation, Miami, Florida, 33125, United States|Brainstorm Research, Miami, Florida, 33176, United States|Brain Matters Research, Stuart, Florida, 34997, United States|Axiom Clinical Research of Florida, Tampa, Florida, 33609, United States|Conquest Research, Winter Park, Florida, 32789, United States|Columbus Memory Center, PC, Columbus, Georgia, 31909, United States|Josephson Wallack Munshower Neurology, PC, Indianapolis, Indiana, 46256, United States|Donald S. Marks M.D., P.C., Plymouth, Massachusetts, 02360, United States|Adams Clinical, Watertown, Massachusetts, 02472, United States|Clinical Research Professionals, Chesterfield, Missouri, 63005, United States|Las Vegas Medical Research, Las Vegas, Nevada, 89113, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, 07081, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, 08755, United States|Neurology Diagnostics, Inc., Dayton, Ohio, 45459, United States|Abington Neurological Associates, Ltd., Abington, Pennsylvania, 19001, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, 19046, United States|Kerwin Medical Center, Dallas, Texas, 75231, United States|National Clinical Research, Inc, Richmond, Virginia, 23294, United States | Study Protocol, https://cdn.clinicaltrials.gov/large-docs/22/NCT05108922/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/22/NCT05108922/SAP_001.pdf                                                                                                                                                                                                                                         |
| ['su+20']                                                                                                                                                                               | NCT05150990  | Technology and Family Thriving Study                                                                                                     | https://clinicaltrials.gov/study/NCT05150990 | Thrive     | COMPLETED             | The purpose of this project is to test the impact of different forms of technology (virtual reality vs. video chat) on quality of life and family relationships in older adults who reside in senior living communities and an adult child who lives at a distance. The study will also investigate whether responses to the technology and quality of life outcomes depend on older adults' level of cognitive impairment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | NO              | Alzheimer Disease|Dementia|Caregiver Burnout|Quality of Life|Mental Health Wellness 1|Loneliness|Family Relationship | BEHAVIORAL: Virtual Reality|BEHAVIORAL: Video Chat                                                                                                                                                                                                                                  | University of California, Santa Barbara                                   | Rendever, Inc.                                                                                                                                                                 | NA            |          372 | OTHER         | INTERVENTIONAL | 2021-10-12   | 2023-12-16                | 2024-03-16        | 2021-12-09     |                        | 2024-03-19           | Belmont Calabasas, Calabasas, California, 91302, United States|Oakmont of Camarillo, Camarillo, California, 93012, United States|Friendship Manor, Goleta, California, 93117, United States|Casa Dorinda, Montecito, California, 93108, United States|Ojai Gables, Ojai, California, 93023, United States|Garden Court on De La Vina, Santa Barbara, California, 93101, United States|Covenant Living at the Samarkand, Santa Barbara, California, 93105, United States|Gardens on Hope, Santa Barbara, California, 93105, United States|Grace Village Apartments, Santa Barbara, California, 93105, United States|Valle Verde, Santa Barbara, California, 93105, United States|Vista Del Monte, Santa Barbara, California, 93105, United States|Heritage House, Santa Barbara, California, 93111, United States|Maravilla, Santa Barbara, California, 93111, United States|Atterdag Village of Solvang, Solvang, California, 93463, United States|Stone Hill at Andover, Andover, Massachusetts, 01810, United States|Stonebridge at Burlington, Burlington, Massachusetts, 01803, United States|Youville House Assisted Living, Cambridge, Massachusetts, 02138, United States|Cadbury Commons, Cambridge, Massachusetts, 02140, United States|Brightview Canton, Canton, Massachusetts, 02021, United States|The Linden at Danvers, Danvers, Massachusetts, 01923, United States|Brightview North Andover, North Andover, Massachusetts, 01845, United States|Benchmark of Norwood (Clapboardtree), Norwood, Massachusetts, 02062, United States|Laurelwood at The Pinehills, Plymouth, Massachusetts, 02630, United States|Autumn Glen at Dartmouth, South Dartmouth, Massachusetts, 02747, United States|Bayberry at Emerald Court, Tewksbury, Massachusetts, 01876, United States|Carriage House at Lee's Farm, Wayland, Massachusetts, 01778, United States|Ledgewood Bay Assisted Living, Milford, New Hampshire, 03055, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Informed Consent Form: Informed Consent for Adult Child (Family Member), https://cdn.clinicaltrials.gov/large-docs/90/NCT05150990/ICF_003.pdf|Informed Consent Form: Informed Consent for Legal Representative, https://cdn.clinicaltrials.gov/large-docs/90/NCT05150990/ICF_004.pdf|Informed Consent Form: Informed Consent for Older Adult (Resident), https://cdn.clinicaltrials.gov/large-docs/90/NCT05150990/ICF_005.pdf |
| ['semaglutide']                                                                                                                                                                         | NCT04982575  | Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes                           | https://clinicaltrials.gov/study/NCT04982575 |            | COMPLETED             | This study looks at how well a new medicine called cagrilintide works together with semaglutide on blood sugar levels in people with type 2 diabetes compared to cagrilintide alone or semaglutide alone.Before a new medicine can be prescribed to people it needs to be tested to see if it is safe and effective.Participants will either get cagrilintide and semaglutide together or cagrilintide and a dummy medicine or semaglutide and a dummy medicine. Which treatment participants get is decided by chance.A dummy medicine (placebo) looks like the study medicine but does not contain any active medicine. The dummy medicine is in the study to see if the study medicine works as expected.Participants will get 2 injections per week on the same day. Participants will take the study medicine with a pen. A pen is a medical tool with a needle used for injections under the skin. The study doctor or staff will show how.The study will last for about 39 weeks. Participants will have 12 visits at the clinic and 5 phone calls with the study doctor.At 6 of the clinic visits participants must not eat and drink for 8 hours before the visit (water is allowed).Women who can become pregnant cannot take part in this study. Only women that are surgically sterilised or post-menopausal are allowed to participate in this study Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period | YES             | Diabetes Mellitus, Type 2                                                                                            | DRUG: Semaglutide 2.4 mg|DRUG: Cagrilintide 2.4 mg|DRUG: Placebo (semaglutide)|DRUG: Placebo (cagrilintide)                                                                                                                                                                         | Novo Nordisk A/S                                                          |                                                                                                                                                                                | PHASE2        |           92 | INDUSTRY      | INTERVENTIONAL | 2021-08-02   | 2022-07-07                | 2022-07-07        | 2021-07-29     | 2023-07-27             | 2023-07-27           | Novo Nordisk Investigational Site, Birmingham, Alabama, 35294, United States|Novo Nordisk Investigational Site, Los Alamitos, California, 90720, United States|Novo Nordisk Investigational Site, Los Angeles, California, 90057, United States|Novo Nordisk Investigational Site, Spring Valley, California, 91978, United States|Novo Nordisk Investigational Site, Golden, Colorado, 80401, United States|Novo Nordisk Investigational Site, Orlando, Florida, 32825, United States|Novo Nordisk Investigational Site, Plantation, Florida, 33324, United States|Novo Nordisk Investigational Site, Honolulu, Hawaii, 96814, United States|Novo Nordisk Investigational Site, Gillespie, Illinois, 62033, United States|Novo Nordisk Investigational Site, Oxon Hill, Maryland, 20745, United States|Novo Nordisk Investigational Site, Greensboro, North Carolina, 27408, United States|Novo Nordisk Investigational Site, Wilmington, North Carolina, 28401, United States|Novo Nordisk Investigational Site, Fargo, North Dakota, 58104, United States|Novo Nordisk Investigational Site, Kingsport, Tennessee, 37660, United States|Novo Nordisk Investigational Site, Dallas, Texas, 75230, United States|Novo Nordisk Investigational Site, Houston, Texas, 77079, United States|Novo Nordisk Investigational Site, Longview, Texas, 75605, United States|Novo Nordisk Investigational Site, Olympia, Washington, 98502, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Study Protocol, https://cdn.clinicaltrials.gov/large-docs/75/NCT04982575/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/75/NCT04982575/SAP_001.pdf                                                                                                                                                                                                                                         |
| ['cbd']                                                                                                                                                                                 | NCT04928287  | Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)                                                     | https://clinicaltrials.gov/study/NCT04928287 | PD         | COMPLETED             | This is a randomized, double-blind, single center, phase 2 study to assess efficacy and safety of multiple HB-adMSCs vs Placebo for the treatment of Parkinson's disease.The trial includes a screening period of up to 4 weeks, a 32-week treatment period, and a safety Follow-up period of 20 weeks after the last investigational product administration.This clinical trial will be open to enroll 24 eligible participants diagnosed with Parkinson's disease. Patients' recruitment will be conducted by the study team, if eligible participants are identified based on eligibility criteria, a screening visit will be scheduled. Informed consent form will be given to the study participants and signed before any study procedures. Informed consent form will include information about the clinical trial and some aspects should be considered during this process.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | YES             | Parkinson Disease                                                                                                    | BIOLOGICAL: HB-adMSCs|OTHER: Placebo                                                                                                                                                                                                                                                | Hope Biosciences Stem Cell Research Foundation                            | Hope Biosciences                                                                                                                                                               | PHASE2        |           24 | OTHER         | INTERVENTIONAL | 2021-06-28   | 2023-02-06                | 2023-02-06        | 2021-06-16     | 2024-05-20             | 2024-05-20           | Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, 77478, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Study Protocol, https://cdn.clinicaltrials.gov/large-docs/87/NCT04928287/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/87/NCT04928287/SAP_001.pdf                                                                                                                                                                                                                                         |
| ['apixaban', 'du-176', 'edoxaban', 'savaysa']                                                                                                                                           | NCT04700826  | Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation                     | https://clinicaltrials.gov/study/NCT04700826 | DaRe2THINK | RECRUITING            | The DaRe2 approach (healthcare Data for pragmatic clinical Research in the NHS - primary 2 secondary) is designed to operationalise efficient, nationwide, primary care approaches for randomised trials embedded within the UK National Health Service (NHS), providing automated screening, targeted patient enrolment and 'no-visit' follow-up through innovations in big data and technology solutions.DaRe2THINK will be the first exemplar of this system, and is appropriately focused on the intersection of key national priorities for healthcare; atrial fibrillation (a heart rhythm condition that will double in prevalence in the next few decades) and the impact this condition has on stroke, thromboembolic events, cognitive impairment and vascular dementia. The trial will test the hypothesis that direct oral anticoagulants (DOACs), now commonly used in older patients with atrial fibrillation (AF), are effective and cost-effective at reducing major adverse clinical events in younger patients at low or intermediate risk of stroke, and can reduce the high rate of cognitive decline. The health technology innovations noted above will allow the investigators to answer this important clinical question, as well as demonstrate the capacity and potential of this system for future, large-scale healthcare-embedded clinical trials for patient benefit.                                                                  | NO              | Atrial Fibrillation                                                                                                  | DRUG: Direct Oral Anticoagulants                                                                                                                                                                                                                                                    | University of Birmingham                                                  | Clinical Practice Research Datalink|University Hospital Birmingham NHS Foundation Trust|University of Oxford|London School of Economics and Political Science|Aston University | PHASE4        |         3000 | OTHER         | INTERVENTIONAL | 2021-06-01   | 2026-01                   | 2031-01           | 2021-01-08     |                        | 2023-05-11           | University Hospitals Birmingham, Birmingham, West Midlands, B15 2TH, United Kingdom                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Study Protocol, https://cdn.clinicaltrials.gov/large-docs/26/NCT04700826/Prot_000.pdf                                                                                                                                                                                                                                                                                                                                         |
| ['.delta.1(2)-trans-cannabidiol', 'epidiolex', 'delta(1(2))-trans-cannabidiol', '(a+/-)-cannabidiol', 'cbd', 'cannabidiol']                                                             | NCT04590495  | The Effects of Cannabidiol on the Driving Ability of Healthy Adults                                                                      | https://clinicaltrials.gov/study/NCT04590495 |            | COMPLETED             | A randomized, parallel-group, double-blind, exploratory two-arm trial to assess the effects of CBD on driving ability along with changes in psychological status (i.e. mood, drowsiness, sedation) and cognitive function. Forty healthy West Virginia University (WVU) students will be allocated and randomized to receive: (1) 300 mg of pure CBD oil or (N=20) (2) placebo matched in appearance and taste (N=20). After consuming the study drug, each individual will participate in a 25-35-minute driving simulation and their driving performance measured. To assess changes in psychological status (i.e. mood, drowsiness, sedation) and drug impairment-related cognitive function, the Visual Analog Mood Scale, Stanford Sleepiness Scale , Digital Symbol Substitution Test, Trail Making Test Part A and B, Psychomotor Vigilance Test, and Simple Reaction Time test will also be administered to participants at baseline (prior to study drug consumption) and following completion of the driving simulation test. The entire protocol will be completed in one day and should take 4-4.5 hours to complete for each participant.                                                                                                                                                                                                                                                                                                               | YES             | Driving Performance|Cognitive Impairment|Sedation Complication|Mood                                                  | DRUG: 300 mg Cannabidiol (CBD) oil|DRUG: Placebo                                                                                                                                                                                                                                    | West Virginia University                                                  |                                                                                                                                                                                | PHASE2        |           40 | OTHER         | INTERVENTIONAL | 2021-04-01   | 2021-12-01                | 2021-12-01        | 2020-10-19     | 2022-09-15             | 2022-09-15           | West Virginia University, Morgantown, West Virginia, 26506, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Study Protocol, Statistical Analysis Plan, and Informed Consent Form, https://cdn.clinicaltrials.gov/large-docs/95/NCT04590495/Prot_SAP_ICF_000.pdf                                                                                                                                                                                                                                                                           |
| ['a-a-1', 'cbd']                                                                                                                                                                        | NCT04493320  | 1/2-Dopaminergic Dysfunction in Late-Life Depression (The D3 Study)                                                                      | https://clinicaltrials.gov/study/NCT04493320 |            | TERMINATED            | Growing evidence suggests that dopamine contributes to key cognitive, emotional, and motor functions across the lifespan. In Late-Life Depression (LLD), dysfunction in these areas is common, predicts poor outcomes, and manifests as difficulties in motivation and effort along with cognitive and gait impairment. While studies of dopamine function in early and midlife depression primarily focus on individuals' ability to feel pleasure and respond to rewards, they often exclude the cognitive and physical function domains relevant for older adults despite a recognized decline in dopamine function with normal aging. The objectives of this collaborative R01 proposal between Columbia University/New York State Psychiatric Institute and Vanderbilt University Medical Center are to: 1) characterize dopaminergic dysfunction in LLD across cognitive, emotional, and motor domains at several levels of analysis (cellular Positron Emission Tomography \[PET\], circuit Magnetic Resonance Imaging \[MRI\], and behavioral / self-report); and 2) examine the responsivity of dopamine-related circuits and behavior to stimulation with carbidopa/levodopa (L-DOPA).                                                                                                                                                                                                                                                                     | YES             | Depression|Cognitive Impairment|Gait Impairment                                                                      | DRUG: Carbidopa/levodopa|DRUG: Placebo                                                                                                                                                                                                                                              | New York State Psychiatric Institute                                      | National Institute of Mental Health (NIMH)|Vanderbilt University Medical Center|Columbia University|Emory University                                                           | PHASE4        |            5 | OTHER         | INTERVENTIONAL | 2021-02-10   | 2021-10-27                | 2021-10-27        | 2020-07-30     | 2023-05-22             | 2023-05-22           | New York State Psychiatric Institute, New York, New York, 10032, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Study Protocol, https://cdn.clinicaltrials.gov/large-docs/20/NCT04493320/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/20/NCT04493320/SAP_001.pdf|Informed Consent Form, https://cdn.clinicaltrials.gov/large-docs/20/NCT04493320/ICF_002.pdf                                                                                                                                             |

### alzheimer
**FDA Approvals**

|   fda_year |   fda_year_approval_count | fda_drug_name   | fda_active_ingredient       | fda_approval_date   | fda_approved_use                                                                                                                                                                     | fda_drug_link                                                                                                                                                                               | fda_press_release                                                                                                                           | fda_drug_trials_snapshot                                                             | fda_2_drug_name   | fda_2_active_ingredient     | fda_2_dosage_form             | fda_2_drug_link                                                                                | fda_2_application_type   |   fda_2_application_num | fda_2_sponsor        | sponsor          |
|-----------:|--------------------------:|:----------------|:----------------------------|:--------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:--------------------------------------------------------------------------------------------------------------------------------------------|:-------------------------------------------------------------------------------------|:------------------|:----------------------------|:------------------------------|:-----------------------------------------------------------------------------------------------|:-------------------------|------------------------:|:---------------------|:-----------------|
|       2024 |                        22 | Kisunla         | donanemab-azbt              | 2024-07-02 00:00:00 | To treat Alzheimer's disease                                                                                                                                                         | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761248s000lbl.pdf                                                                                                                 | nan                                                                                                                                         | nan                                                                                  | KISUNLA           | KISUNLA (DONANEMAB-AZBT)    | ['INJECTABLE', 'INJECTION']   | https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761248 | BLA                      |                  761248 | ELI LILLY CO         | Eli Lilly        |
|       2023 |                         1 | Leqembi         | lecanemab-irmb              | 2023-01-06 00:00:00 | To treat Alzheimer‚Äôs diseasePress Release                                                                                                                                          | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s000lbl.pdf                                                                                                            | https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment                            | nan                                                                                  | LEQEMBI           | LEQEMBI (LECANEMAB-IRMB)    | ['INJECTABLE', 'INJECTION']   | https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761269 | BLA                      |                  761269 | EISAI INC            | Eisai            |
|       2021 |                        26 | Aduhelm         | aducanumab-avwa             | 2021-06-07 00:00:00 | To treat Alzheimer‚Äôs diseasePress ReleaseDrug Trials Snapshots                                                                                                                     | http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761178                                                                                            | https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug                                         | https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-aduhelm | ADUHELM           | ADUHELM (ADUCANUMAB-AVWA)   | ['INJECTABLE', 'INJECTION']   | https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761178 | BLA                      |                  761178 | BIOGEN INC           | Biogen           |
|       2020 |                        22 | Tauvid          | flortaucipir F18            | 2020-05-28 00:00:00 | Diagnostic agent for patients with Alzheimer‚Äôs diseasePress ReleaseDrug Trials Snapshot                                                                                            | http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212123                                                                                            | https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-image-tau-pathology-patients-being-evaluated-alzheimers-disease | nan                                                                                  | TAUVID            | TAUVID (FLORTAUCIPIR F-18)  | ['SOLUTION', 'INTRAVENOUS']   | https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212123 | NDA                      |                  212123 | AVID RADIOPHARMS INC | Avid Radiopharms |
|       2013 |                        20 | Vizamyl         | flutemetamol F 18 injection | 2013-10-25 00:00:00 | A†radioactive diagnostic drug for use with positron emission tomography (PET) imaging of the brain in adults being evaluated for Alzheimer's disease (AD) and dementia.Press Release | https://wayback.archive-it.org//7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203137&SearchType=BasicSearch | https://wayback.archive-it.org///7993/20161022052135/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm372261.htm                | nan                                                                                  | VIZAMYL           | VIZAMYL (FLUTEMETAMOL F-18) | ['INJECTABLE', 'INTRAVENOUS'] | https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203137 | NDA                      |                  203137 | GE HEALTHCARE        | Ge               |

**Clinical Trial Sponsors**
![sponsor_plot](images/sponsor_plot_alzheimer.png)

| Search Term                                                                                                                                                                             | NCT Number   | Study Title                                                                                                                              | Study URL                                    | Acronym    | Study Status          | Brief Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Study Results   | Conditions                                                                                                           | Interventions                                                   | Sponsor                                 | Collaborators                                                                                              | Phases   |   Enrollment | Funder Type   | Study Type     | Start Date   | Primary Completion Date   | Completion Date   | First Posted   | Results First Posted   | Last Update Posted   | Locations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Study Documents                                                                                                                                                                                                                                                                                                                                                                                                               |
|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:-------------|:-----------------------------------------------------------------------------------------------------------------------------------------|:---------------------------------------------|:-----------|:----------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----------------|:---------------------------------------------------------------------------------------------------------------------|:----------------------------------------------------------------|:----------------------------------------|:-----------------------------------------------------------------------------------------------------------|:---------|-------------:|:--------------|:---------------|:-------------|:--------------------------|:------------------|:---------------|:-----------------------|:---------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ['cannabidiol', 'epidiolex', '(a+/-)-cannabidiol', 'cbd']                                                                                                                               | NCT06069713  | Consumer Perceptions of Cannabidiol (CBD) Health Claims                                                                                  | https://clinicaltrials.gov/study/NCT06069713 | CBD        | COMPLETED             | Over 46 million US adults report use of cannabidiol (CBD), primarily to treat medical ailments. The growing CBD market spans the range of products that the US Food and Drug Administration (FDA) regulates including drugs, dietary supplements, food/beverages and cosmetics. CBD cannot be marketed as having therapeutic benefits (without FDA's approval), be false or misleading to consumers, or convey the products are approved or endorsed by the FDA. In addition, CBD cannot be marketed as a food additive or dietary supplement since it is an active ingredient in an approved drug, Epidiolex. Despite this, CBD products have been illicitly advertised to consumers with these claims including unsubstantiated health claims that promote benefits including curing cancer and preventing Alzheimer's disease. These types of claims may reduce perceptions of harm and increase perceived benefits of use. This study aims to evaluate how consumers perceive real-world CBD advertisements. To that end, we will implement an online survey and randomize adult participants (ages 18-65) to see various advertisements made about CBD to determine if they interpret advertisements as making health claims that are currently prohibited by the FDA.                                                                                                                                                                                                                                                                                                                                                                         | NO              | Perceptions                                                                                                          | BEHAVIORAL: CBD advertisements                                  | Wake Forest University Health Sciences  | National Institute on Drug Abuse (NIDA)|University of North Carolina, Chapel Hill|Public Health Law Center | NA       |         3525 | OTHER         | INTERVENTIONAL | 2023-10-09   | 2023-11-20                | 2023-11-20        | 2023-10-06     |                        | 2024-05-02           | Wake Forest University Health Sciences, Winston-Salem, North Carolina, 27157, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Informed Consent Form, https://cdn.clinicaltrials.gov/large-docs/13/NCT06069713/ICF_000.pdf                                                                                                                                                                                                                                                                                                                                   |
| ['example+9']                                                                                                                                                                           | NCT05734638  | Stress and Blood Pressure Management for Caregivers                                                                                      | https://clinicaltrials.gov/study/NCT05734638 | Stress/HTN | RECRUITING            | Due to health and wealth disparities, no demographic group is more at risk than African American women for the double jeopardy of stress from caregiving for persons living with dementia (PLWD) and stress associated with hypertension (HTN). This double jeopardy puts those they care for in jeopardy as well: Reduced quality of life and longevity, disability, cognitive decline, and stroke associated with HTN1 impede caregiving activities and resultant health and well-being for persons living with Alzheimer's disease and related dementias (ADRD). Although successful multi-component interventions have addressed ADRD caregiver stress (REACH II) and the Savvy Caregiver program, to our knowledge there are no interventions that target the complexity of chronic caregiving stress and HTN self-care for African American women caregivers of persons living with ADRD.This project will test two interventions for their effectiveness in improving outcomes for the target group: Mindfulness in Motion (MIM) and the Dietary Approaches to Stop Hypertension (DASH). MIM includes mindful awareness and movement from a seated position, breathing exercises, healthy sleep, and guided mindfulness meditation. The DASH component will be tailored for Black Americans. It uses a critical thinking approach that involves problem solving, participant-centered goal setting, health coaching, reflection, and development of self-efficacy (confidence) to promote physical activity and healthy eating. Solid empirical evidence demonstrates its effectiveness in reducing blood pressure among mixed-race samples. | NO              | Hypertension|Stress, Psychological                                                                                   | BEHAVIORAL: MIM-DASH|BEHAVIORAL: MIM Only|BEHAVIORAL: DASH Only | Ohio State University                   | Robert Wood Johnson Foundation                                                                             | NA       |           90 | OTHER         | INTERVENTIONAL | 2023-09-11   | 2025-09-30                | 2026-09-30        | 2023-02-21     |                        | 2023-09-28           | Ohio State University, Columbus, Ohio, 43210, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/38/NCT05734638/Prot_SAP_000.pdf|Informed Consent Form, https://cdn.clinicaltrials.gov/large-docs/38/NCT05734638/ICF_001.pdf                                                                                                                                                                                                           |
| ['lemborexant', 'dayvigo']                                                                                                                                                              | NCT05728736  | Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau                                                                                  | https://clinicaltrials.gov/study/NCT05728736 |            | WITHDRAWN             | This study will look at the effects of lemborexant on Alzheimer's disease biomarkers found in the cerebrospinal fluid (CSF) and blood in individuals who are poor sleepers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | NO              | Alzheimer Disease                                                                                                    | DRUG: Lemborexant 25 mg|DRUG: Placebo                           | Brendan Lucey                           | Eisai Inc.                                                                                                 | PHASE2   |            0 | OTHER         | INTERVENTIONAL | 2023-03-01   | 2023-09-27                | 2023-10-04        | 2023-02-15     |                        | 2023-11-08           | Washington University School of Medicine, Saint Louis, Missouri, 63110, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/36/NCT05728736/Prot_SAP_000.pdf|Informed Consent Form, https://cdn.clinicaltrials.gov/large-docs/36/NCT05728736/ICF_001.pdf                                                                                                                                                                                                           |
| ['example+9']                                                                                                                                                                           | NCT05721482  | Stress and Hypertension in Dementia Caregivers                                                                                           | https://clinicaltrials.gov/study/NCT05721482 | MIM-DASH   | ACTIVE_NOT_RECRUITING | No demographic group is more at risk for the double jeopardy of caregiving stress and hypertension (HTN) than African American women caring for a family member with Alzheimer's disease and related dementias (ADRD). Both situations lead to reduced quality of life and cardiovascular disease-a complication of uncontrolled hypertension. Maintaining the health of these caregivers is critical to support the well-being of the care recipients. Although some multi-component interventions have addressed ADRD caregiver's stress and quality of life, gaps remain in targeting interventions to address the complexity of chronic caregiving stress and hypertension self-care in African American women.This pilot study builds on the investigator's earlier work which showed that stress, blood pressure knowledge, and complex diet information deficits all interfered with older African American women's hypertension self-care. Lifestyle changes (stress management, reducing sodium, eating fruits/vegetables, and physical activity) are effective in managing hypertension. The investigator's Stage I pilot study is based on the scientific rationale that these lifestyle changes can be promoted by addressing stress reactivity/stress resilience, the psychological and physiological response of the body to stress, as the underlying mechanism to facilitate behavioral change. In this way the study can improve health outcomes (caregiver stress, quality of life, cardiovascular disease risk).                                                                                                                 | NO              | Hypertension|Stress, Psychological                                                                                   | BEHAVIORAL: Caregiver Training                                  | Ohio State University                   | National Institute on Aging (NIA)                                                                          | NA       |           28 | OTHER         | INTERVENTIONAL | 2023-01-17   | 2023-10-15                | 2024-10-15        | 2023-02-10     |                        | 2024-06-07           | College of Nursing Ohio State University, Columbus, Ohio, 43210, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/82/NCT05721482/Prot_SAP_000.pdf|Informed Consent Form, https://cdn.clinicaltrials.gov/large-docs/82/NCT05721482/ICF_001.pdf                                                                                                                                                                                                           |
| ['alogliptine', 'syr-322', 'syr+322', 'alogliptin', 'semaglutide', 'nesina', 'alogliptina', 'alogliptinum', 'syr322']                                                                   | NCT05768945  | Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors                            | https://clinicaltrials.gov/study/NCT05768945 |            | ACTIVE_NOT_RECRUITING | This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | NO              | Diabetes                                                                                                             | DRUG: Semaglutide|DRUG: DPP-4 inhibitor                         | Brigham and Women's Hospital            | National Institute on Aging (NIA)|Rutgers University|Johns Hopkins University                              |          |       742670 | OTHER         | OBSERVATIONAL  | 2022-11-30   | 2023-07-07                | 2023-12-31        | 2023-03-15     |                        | 2023-07-19           | Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/45/NCT05768945/Prot_SAP_000.pdf                                                                                                                                                                                                                                                                                                       |
| ['example+9']                                                                                                                                                                           | NCT04418232  | Feasibility of a Systems Approach for Alzheimer's Services Among Latinos Attending Primary Care Practices                                | https://clinicaltrials.gov/study/NCT04418232 |            | RECRUITING            | The research team will train primary care practitioners from Kansas City clinics to enhance skills in cultural competence, dementia detection, treatment and referral to a Health Navigator among Latinos 65 and older with dementia. The Health Navigator will provide patient/caregiver dyads referred by Alianza Latina providers with care management, psychosocial support and links to relevant community resources. Outcomes include feasibility and acceptability of 1) PCP training and 2) patient and caregiver dementia care.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | NO              | Dementia                                                                                                             | COMBINATION_PRODUCT: Alianza Latina                             | University of Kansas Medical Center     | National Institute on Minority Health and Health Disparities (NIMHD)                                       | PHASE1   |          100 | OTHER         | INTERVENTIONAL | 2022-05-01   | 2024-12-01                | 2025-01-01        | 2020-06-05     |                        | 2023-10-31           | University of Kansas Medical Center, Kansas City, Kansas, 66103, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/32/NCT04418232/Prot_SAP_000.pdf|Informed Consent Form, https://cdn.clinicaltrials.gov/large-docs/32/NCT04418232/ICF_001.pdf                                                                                                                                                                                                           |
| ['suv', 'florbetapir+f18', 'amyvid', '18f-av45', 'florbetapir-fluorine-18', 'florbetapir,+f-18', 'aducanumab-avwa', 'florbetapir+f+18', 'florbetapir+f-18', '18f-av-45', 'florbetapir'] | NCT05108922  | A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4) | https://clinicaltrials.gov/study/NCT05108922 |            | COMPLETED             | The main purpose of this study is to compare donanemab to aducanumab on brain amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | YES             | Mild Cognitive Impairment (MCI)|Alzheimer Disease                                                                    | DRUG: Donanemab|DRUG: Aducanumab                                | Eli Lilly and Company                   |                                                                                                            | PHASE3   |          148 | INDUSTRY      | INTERVENTIONAL | 2021-11-16   | 2022-09-09                | 2023-09-19        | 2021-11-05     | 2023-11-02             | 2023-11-02           | Neurology Center of North Orange County, Fullerton, California, 92835, United States|Irvine Clinical Research, Irvine, California, 92614, United States|California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, 91403, United States|Institute for Neurodegenerative Disorders, New Haven, Connecticut, 06510, United States|JEM Research Institute, Atlantis, Florida, 33462, United States|Brain Matters Research, Delray Beach, Florida, 33445, United States|Neuropsychiatric Research Center of Southwest Florida, Fort Myers, Florida, 33912, United States|Infinity Clinical Research, LLC, Hollywood, Florida, 33024, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, 32216, United States|Charter Research - Lady Lake, Lady Lake, Florida, 32159, United States|ClinCloud - Maitland, Maitland, Florida, 32751, United States|ClinCloud - Viera, Melbourne, Florida, 32940, United States|Merritt Island Medical Research, LLC, Merritt Island, Florida, 32952, United States|Optimus U Corporation, Miami, Florida, 33125, United States|Brainstorm Research, Miami, Florida, 33176, United States|Brain Matters Research, Stuart, Florida, 34997, United States|Axiom Clinical Research of Florida, Tampa, Florida, 33609, United States|Conquest Research, Winter Park, Florida, 32789, United States|Columbus Memory Center, PC, Columbus, Georgia, 31909, United States|Josephson Wallack Munshower Neurology, PC, Indianapolis, Indiana, 46256, United States|Donald S. Marks M.D., P.C., Plymouth, Massachusetts, 02360, United States|Adams Clinical, Watertown, Massachusetts, 02472, United States|Clinical Research Professionals, Chesterfield, Missouri, 63005, United States|Las Vegas Medical Research, Las Vegas, Nevada, 89113, United States|The Cognitive and Research Center of New Jersey, Springfield, New Jersey, 07081, United States|Advanced Memory Research Institute of New Jersey, Toms River, New Jersey, 08755, United States|Neurology Diagnostics, Inc., Dayton, Ohio, 45459, United States|Abington Neurological Associates, Ltd., Abington, Pennsylvania, 19001, United States|The Clinical Trial Center, LLC, Jenkintown, Pennsylvania, 19046, United States|Kerwin Medical Center, Dallas, Texas, 75231, United States|National Clinical Research, Inc, Richmond, Virginia, 23294, United States | Study Protocol, https://cdn.clinicaltrials.gov/large-docs/22/NCT05108922/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/22/NCT05108922/SAP_001.pdf                                                                                                                                                                                                                                         |
| ['su+20']                                                                                                                                                                               | NCT05150990  | Technology and Family Thriving Study                                                                                                     | https://clinicaltrials.gov/study/NCT05150990 | Thrive     | COMPLETED             | The purpose of this project is to test the impact of different forms of technology (virtual reality vs. video chat) on quality of life and family relationships in older adults who reside in senior living communities and an adult child who lives at a distance. The study will also investigate whether responses to the technology and quality of life outcomes depend on older adults' level of cognitive impairment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | NO              | Alzheimer Disease|Dementia|Caregiver Burnout|Quality of Life|Mental Health Wellness 1|Loneliness|Family Relationship | BEHAVIORAL: Virtual Reality|BEHAVIORAL: Video Chat              | University of California, Santa Barbara | Rendever, Inc.                                                                                             | NA       |          372 | OTHER         | INTERVENTIONAL | 2021-10-12   | 2023-12-16                | 2024-03-16        | 2021-12-09     |                        | 2024-03-19           | Belmont Calabasas, Calabasas, California, 91302, United States|Oakmont of Camarillo, Camarillo, California, 93012, United States|Friendship Manor, Goleta, California, 93117, United States|Casa Dorinda, Montecito, California, 93108, United States|Ojai Gables, Ojai, California, 93023, United States|Garden Court on De La Vina, Santa Barbara, California, 93101, United States|Covenant Living at the Samarkand, Santa Barbara, California, 93105, United States|Gardens on Hope, Santa Barbara, California, 93105, United States|Grace Village Apartments, Santa Barbara, California, 93105, United States|Valle Verde, Santa Barbara, California, 93105, United States|Vista Del Monte, Santa Barbara, California, 93105, United States|Heritage House, Santa Barbara, California, 93111, United States|Maravilla, Santa Barbara, California, 93111, United States|Atterdag Village of Solvang, Solvang, California, 93463, United States|Stone Hill at Andover, Andover, Massachusetts, 01810, United States|Stonebridge at Burlington, Burlington, Massachusetts, 01803, United States|Youville House Assisted Living, Cambridge, Massachusetts, 02138, United States|Cadbury Commons, Cambridge, Massachusetts, 02140, United States|Brightview Canton, Canton, Massachusetts, 02021, United States|The Linden at Danvers, Danvers, Massachusetts, 01923, United States|Brightview North Andover, North Andover, Massachusetts, 01845, United States|Benchmark of Norwood (Clapboardtree), Norwood, Massachusetts, 02062, United States|Laurelwood at The Pinehills, Plymouth, Massachusetts, 02630, United States|Autumn Glen at Dartmouth, South Dartmouth, Massachusetts, 02747, United States|Bayberry at Emerald Court, Tewksbury, Massachusetts, 01876, United States|Carriage House at Lee's Farm, Wayland, Massachusetts, 01778, United States|Ledgewood Bay Assisted Living, Milford, New Hampshire, 03055, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Informed Consent Form: Informed Consent for Adult Child (Family Member), https://cdn.clinicaltrials.gov/large-docs/90/NCT05150990/ICF_003.pdf|Informed Consent Form: Informed Consent for Legal Representative, https://cdn.clinicaltrials.gov/large-docs/90/NCT05150990/ICF_004.pdf|Informed Consent Form: Informed Consent for Older Adult (Resident), https://cdn.clinicaltrials.gov/large-docs/90/NCT05150990/ICF_005.pdf |
| ['macitentan']                                                                                                                                                                          | NCT05039086  | Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5 Inhibitors vs Endothelin Receptor Antagonist       | https://clinicaltrials.gov/study/NCT05039086 |            | COMPLETED             | This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | YES             | Pulmonary Arterial Hypertension                                                                                      | DRUG: PDE5 inhibitor|DRUG: Endothelin Receptor Antagonists      | Brigham and Women's Hospital            | National Institute on Aging (NIA)|Rutgers University|Johns Hopkins University                              |          |        13021 | OTHER         | OBSERVATIONAL  | 2021-09-01   | 2021-09-30                | 2022-10-04        | 2021-09-09     | 2024-02-20             | 2024-04-30           | Brigham and Women's Hospital, Boston, Massachusetts, 02120, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/86/NCT05039086/Prot_SAP_001.pdf                                                                                                                                                                                                                                                                                                       |
| ['gsk-573719', 'incruse', 'aclidinium+bromide', 'aclidinium+bromide?']                                                                                                                  | NCT05457868  | Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Salbutamol vs Long-acting Muscarinic Antagonists        | https://clinicaltrials.gov/study/NCT05457868 |            | ACTIVE_NOT_RECRUITING | This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | NO              | Chronic Obstructive Pulmonary Disease                                                                                | DRUG: Salbutamol|DRUG: LAMA                                     | Brigham and Women's Hospital            | National Institute on Aging (NIA)|Rutgers University|Johns Hopkins University                              |          |       124117 | OTHER         | OBSERVATIONAL  | 2021-02-01   | 2022-07-30                | 2023-12-31        | 2022-07-14     |                        | 2023-07-18           | Brigham and Women's Hospital, Boston, Massachusetts, 02120, United States                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/68/NCT05457868/Prot_SAP_001.pdf                                                                                                                                                                                                                                                                                                       |

